AR034813A1 - Composiciones farmaceuticas y uso de las mismas - Google Patents

Composiciones farmaceuticas y uso de las mismas

Info

Publication number
AR034813A1
AR034813A1 ARP020102698A ARP020102698A AR034813A1 AR 034813 A1 AR034813 A1 AR 034813A1 AR P020102698 A ARP020102698 A AR P020102698A AR P020102698 A ARP020102698 A AR P020102698A AR 034813 A1 AR034813 A1 AR 034813A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
same
minitabletas
capsules
minimizing
Prior art date
Application number
ARP020102698A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27256227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR034813(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0117760A external-priority patent/GB0117760D0/en
Priority claimed from GB0128993A external-priority patent/GB0128993D0/en
Priority claimed from GB0212209A external-priority patent/GB0212209D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR034813A1 publication Critical patent/AR034813A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ARP020102698A 2001-07-20 2002-07-18 Composiciones farmaceuticas y uso de las mismas AR034813A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0117760A GB0117760D0 (en) 2001-07-20 2001-07-20 Organic compounds
GB0128993A GB0128993D0 (en) 2001-12-04 2001-12-04 Organic compounds
GB0212209A GB0212209D0 (en) 2002-05-27 2002-05-27 Organic compounds

Publications (1)

Publication Number Publication Date
AR034813A1 true AR034813A1 (es) 2004-03-17

Family

ID=27256227

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102698A AR034813A1 (es) 2001-07-20 2002-07-18 Composiciones farmaceuticas y uso de las mismas

Country Status (27)

Country Link
US (2) US20040198838A1 (cg-RX-API-DMAC7.html)
EP (1) EP1411921B2 (cg-RX-API-DMAC7.html)
JP (3) JP2005503399A (cg-RX-API-DMAC7.html)
KR (2) KR100651110B1 (cg-RX-API-DMAC7.html)
CN (1) CN100358518C (cg-RX-API-DMAC7.html)
AR (1) AR034813A1 (cg-RX-API-DMAC7.html)
AT (1) ATE381329T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002321249B2 (cg-RX-API-DMAC7.html)
BR (1) BR0211198A (cg-RX-API-DMAC7.html)
CA (1) CA2453263C (cg-RX-API-DMAC7.html)
CY (1) CY1107861T1 (cg-RX-API-DMAC7.html)
DE (1) DE60224194T3 (cg-RX-API-DMAC7.html)
DK (1) DK1411921T4 (cg-RX-API-DMAC7.html)
ES (1) ES2295381T5 (cg-RX-API-DMAC7.html)
HU (1) HUP0401200A3 (cg-RX-API-DMAC7.html)
IL (2) IL159591A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000627A (cg-RX-API-DMAC7.html)
MY (1) MY136136A (cg-RX-API-DMAC7.html)
NO (1) NO332268B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ530648A (cg-RX-API-DMAC7.html)
PE (1) PE20030287A1 (cg-RX-API-DMAC7.html)
PL (1) PL365416A1 (cg-RX-API-DMAC7.html)
PT (1) PT1411921E (cg-RX-API-DMAC7.html)
RU (1) RU2298402C2 (cg-RX-API-DMAC7.html)
SI (1) SI1411921T2 (cg-RX-API-DMAC7.html)
TW (1) TWI302460B (cg-RX-API-DMAC7.html)
WO (1) WO2003022267A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR034813A1 (es) † 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
AU2003244633A1 (en) * 2002-07-02 2004-01-23 Novartis Ag Methods for the treatment of sinusitis
JP2005060310A (ja) * 2003-08-13 2005-03-10 Towa Yakuhin Kk 不快な味をマスキングする経口投与用製剤
JP2005187339A (ja) * 2003-12-24 2005-07-14 Iwaki Seiyaku Co Ltd 耐光性塩酸テルビナフィンフィルムコート錠
JP4999297B2 (ja) * 2005-08-10 2012-08-15 高田製薬株式会社 高含量塩酸テルビナフィン小型錠剤
US8815285B2 (en) * 2006-03-28 2014-08-26 Wockhardt Ltd. Extended release dosage forms of metoprolol
CN1820744B (zh) * 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 磷酸奥司他韦颗粒剂及其制备方法
WO2007121537A1 (en) * 2006-04-26 2007-11-01 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
RU2451504C2 (ru) * 2006-06-07 2012-05-27 Новартис Аг Способ получения мультичастиц с применением роликового компактора
KR20110117199A (ko) * 2009-01-28 2011-10-26 노파르티스 아게 유기 화합물의 생약 제제
WO2010086727A1 (en) * 2009-01-30 2010-08-05 Galderma Pharma Sa Stable compositions for nail onychomycosis treatment
CN102198111A (zh) * 2011-06-17 2011-09-28 哈尔滨乐泰药业有限公司 一种抗真菌药物片剂的制备方法
WO2013043143A1 (ru) * 2011-09-21 2013-03-28 Slyusar Viktor Timopheevich Способ снижения лишнего веса
EP2822542A1 (en) * 2012-03-07 2015-01-14 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
LT3429559T (lt) 2016-03-15 2022-08-10 Acer Therapeutics Inc. Skanios kompozicijos, įskaitant natrio fenilbutiratą, ir jų panaudojimas
WO2018069388A1 (en) 2016-10-11 2018-04-19 Khalifa University of Science and Technology Coated chloride salt particles and methods of making and using the same
FR3069545B1 (fr) * 2017-07-27 2020-10-16 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition d'enrobage exempte de dioxyde de titane
CN109833301A (zh) * 2017-11-29 2019-06-04 天津市保灵动物保健品有限公司 一种犬猫用盐酸特比萘芬风味片及其制备工艺
CN109925296B (zh) * 2017-12-19 2021-09-07 四川济生堂药业有限公司 一种中药微丸的包衣方法
CN112156078A (zh) * 2020-11-11 2021-01-01 乐泰药业有限公司 一种盐酸特比萘芬片、其制备方法以及杂质与质量检测方法
AU2021391823A1 (en) 2020-12-03 2023-06-29 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
IL307454A (en) 2021-04-07 2023-12-01 Battelle Memorial Institute Technologies for rapid design, construction, testing, learning to identify and use non-viral vectors
CN115869273B (zh) * 2022-10-31 2025-09-30 修正药业集团长春高新制药有限公司 一种盐酸特比萘芬片及其制备方法
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62184D0 (da) † 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
EP0166315B1 (de) * 1984-06-19 1989-08-23 BASF Aktiengesellschaft Magensaftresistent überzogene zylindrische Pankreatin-Mikrotabletten
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4894375A (en) * 1986-09-29 1990-01-16 Merck & Co., Inc. Method of controlling mycotic infections and compositions therefor
RU2033991C1 (ru) * 1989-06-08 1995-04-30 Ф.Хоффманн-Ля Рош Аг Производные аминоалкилбензола или их фармацевтически приемлемые соли с кислотами
DE3937455A1 (de) * 1989-11-10 1991-05-16 Nordmark Arzneimittel Gmbh Antacidatabletten
GB9111477D0 (en) * 1991-05-29 1991-07-17 Sandoz Ltd Pharmaceutical composition
US5262172A (en) * 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US5578304A (en) * 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5415872A (en) * 1992-06-22 1995-05-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5234697A (en) * 1992-06-22 1993-08-10 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5332727A (en) * 1993-04-29 1994-07-26 Birkmayer U.S.A. Stable, ingestable and absorbable NADH and NADPH therapeutic compositions
AU1313695A (en) * 1993-12-14 1995-07-03 Sandoz Ltd. Pharmaceutical compositions containing alkyl polyoxyalkylene carboxylates
FR2722102B1 (fr) * 1994-07-11 1996-08-23 Cird Galderma Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
NZ280065A (en) * 1995-09-20 1998-04-27 Apotex Inc Preparation of n-alkyl-n-(1-naphthylmethyl)alk-2-en-4-ynylamine derivatives
FR2751878B1 (fr) * 1996-07-30 1998-09-04 Oreal Utilisation dans une composition d'un extrait d'au moins une labiee
CA2184535C (en) * 1996-08-30 2000-04-18 H. Craig Willis Apparatus and method for separation of solids from liquid
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
FR2755011B1 (fr) * 1996-10-31 1998-11-20 Cird Galderma Utilisation des inhibiteurs de l'activite de l'acide retinoique pour traiter les peaux sensibles et/ou les dommages aigus induits par les rayonnements u.v.
HUP0002744A3 (en) * 1997-01-06 2001-01-29 Pfizer Rapidly releasing and taste-masking pharmaceutical dosage form
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
FR2771291B1 (fr) † 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
DE19842753A1 (de) † 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
WO2000030617A1 (en) * 1998-11-25 2000-06-02 Cima Labs Inc. Taste masking rapid release coating system
US6740341B1 (en) * 1998-11-25 2004-05-25 Cima Labs Inc. Taste masking rapid release coating system
DK1146862T3 (da) † 1999-01-29 2003-07-21 Disphar Int Bv Farmaceutiske sammensætninger
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
CN1116033C (zh) * 1999-07-08 2003-07-30 齐鲁制药厂 一种治疗阴道炎的泡腾片剂及其制法
EP1202716A1 (en) * 1999-08-17 2002-05-08 Novartis Consumer Health S.A. Rapidly dissolving dosage form and process for making same
GB0001315D0 (en) * 2000-01-20 2000-03-08 Novartis Ag Organic compounds
AU2001239838A1 (en) † 2000-02-24 2001-09-03 Advancis Pharmaceutical Corporation Therapeutic product, use and formulation thereof
DE10017996A1 (de) * 2000-04-11 2001-10-18 Pierre Foss Lamisil-Intervall-System
GB0014448D0 (en) * 2000-06-13 2000-08-09 Novartis Ag Organic compounds
AR034813A1 (es) † 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
US20040198828A1 (en) * 2003-01-17 2004-10-07 Abelson Mark B. Combinational use of long-acting and short-acting anti-histamines for ocular allergies

Also Published As

Publication number Publication date
AU2002321249B2 (en) 2005-10-27
ATE381329T1 (de) 2008-01-15
KR20060076331A (ko) 2006-07-04
CA2453263C (en) 2010-12-07
ES2295381T5 (es) 2011-01-31
RU2298402C2 (ru) 2007-05-10
PL365416A1 (en) 2005-01-10
PT1411921E (pt) 2008-03-12
US20040198838A1 (en) 2004-10-07
EP1411921B1 (en) 2007-12-19
ES2295381T3 (es) 2008-04-16
DE60224194T2 (de) 2008-12-24
HUP0401200A3 (en) 2008-03-28
DK1411921T4 (da) 2010-11-08
NZ530648A (en) 2007-04-27
KR100651110B1 (ko) 2006-12-21
PE20030287A1 (es) 2003-05-06
BR0211198A (pt) 2004-08-10
SI1411921T2 (sl) 2010-12-31
WO2003022267A1 (en) 2003-03-20
JP2005503399A (ja) 2005-02-03
IL159591A (en) 2012-06-28
JP2008280351A (ja) 2008-11-20
HUP0401200A2 (hu) 2004-10-28
CN100358518C (zh) 2008-01-02
NO20040254L (no) 2004-03-22
IL159591A0 (en) 2004-06-01
US20080286356A1 (en) 2008-11-20
MY136136A (en) 2008-08-29
KR20040028935A (ko) 2004-04-03
MXPA04000627A (es) 2004-04-20
TWI302460B (en) 2008-11-01
NO332268B1 (no) 2012-08-13
RU2004105263A (ru) 2005-04-20
DE60224194T3 (de) 2011-03-17
JP2012136523A (ja) 2012-07-19
DK1411921T3 (da) 2008-04-21
SI1411921T1 (sl) 2008-06-30
KR100699958B1 (ko) 2007-03-28
DE60224194D1 (de) 2008-01-31
EP1411921A1 (en) 2004-04-28
CA2453263A1 (en) 2003-03-20
CN1527706A (zh) 2004-09-08
CY1107861T1 (el) 2013-06-19
HK1067299A1 (en) 2005-04-08
EP1411921B2 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
ECSP083351A (es) Composiciones farmacéuticas
AR065970A2 (es) Una composicion farmaceutica oral solida que comprende una combinacion de metformin y glibenclamida y uso de dicha composicion
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
BR0108584A (pt) Formulações contendo um fármaco anticolinérgico para o tratamento da broncopneumopatia crÈnica obtrutiva
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
AR006678A1 (es) Derivados de macrolidas triciclicas, una composicion farmaceutica que los contiene, uso de los mismos para preparar medicamentos y procedimientopara su preparacion
SE0003449D0 (sv) Anticancer compositions
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
HUP0401224A2 (hu) Eljárás gyógyászati készítmények előállítására lágyzselatin-összetételekkel való felhasználás céljára
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
PA8542701A1 (es) Composición parenteral reconstituible
DE60019334D1 (de) Antivirale arznei
AR034517A1 (es) Formulacion farmaceutica
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
BR0312728A (pt) Formulação em tablete dispersìvel e processo para sua preparação
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
AR033596A1 (es) Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple
BR112022008192A2 (pt) Queratina bd-4, sua preparação e composições farmacêuticas e uso
ECSP024290A (es) Composiciones farmacéuticas y uso de las mismas

Legal Events

Date Code Title Description
FB Suspension of granting procedure